Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.58
REGN's Cash to Debt is ranked higher than
61% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. REGN: 1.58 )
REGN' s 10-Year Cash to Debt Range
Min: 0.57   Max: No Debt
Current: 1.58

Equity to Asset 0.69
REGN's Equity to Asset is ranked higher than
75% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. REGN: 0.69 )
REGN' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.93
Current: 0.69

0.18
0.93
Interest Coverage 16.37
REGN's Interest Coverage is ranked higher than
54% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 16.37 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 16.37
Current: 16.37

0.46
16.37
F-Score: 4
Z-Score: 21.11
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 36.11
REGN's Operating margin (%) is ranked higher than
97% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. REGN: 36.11 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 36.11

-554.63
187.97
Net-margin (%) 20.16
REGN's Net-margin (%) is ranked higher than
93% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. REGN: 20.16 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 20.16

-565.66
54.43
ROE (%) 21.74
REGN's ROE (%) is ranked higher than
96% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. REGN: 21.74 )
REGN' s 10-Year ROE (%) Range
Min: -85.2   Max: 60.24
Current: 21.74

-85.2
60.24
ROA (%) 14.38
REGN's ROA (%) is ranked higher than
96% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. REGN: 14.38 )
REGN' s 10-Year ROA (%) Range
Min: -31.76   Max: 36.06
Current: 14.38

-31.76
36.06
ROC (Joel Greenblatt) (%) 57.06
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. REGN: 57.06 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -218.13   Max: 197.42
Current: 57.06

-218.13
197.42
Revenue Growth (%) 50.60
REGN's Revenue Growth (%) is ranked higher than
97% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. REGN: 50.60 )
REGN' s 10-Year Revenue Growth (%) Range
Min: -25.3   Max: 81.3
Current: 50.6

-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

REGN Guru Trades in Q3 2013

Joel Greenblatt 3,285 sh (New)
Frank Sands 3,777,357 sh (+20.34%)
Jim Simons 249,521 sh (+6.29%)
Vanguard Health Care Fund 1,412,100 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 1,420 sh (-95.72%)
» More
Q4 2013

REGN Guru Trades in Q4 2013

Steven Cohen 28,304 sh (+1893.24%)
Vanguard Health Care Fund 1,412,100 sh (unchged)
Joel Greenblatt Sold Out
Frank Sands 3,732,680 sh (-1.18%)
Jim Simons 70,062 sh (-71.92%)
» More
Q1 2014

REGN Guru Trades in Q1 2014

Andreas Halvorsen 1,051,800 sh (New)
Ron Baron 6,084 sh (New)
Paul Tudor Jones 893 sh (New)
Steven Cohen 65,232 sh (+130.47%)
Vanguard Health Care Fund 1,743,468 sh (+23.47%)
Frank Sands 4,012,062 sh (+7.48%)
Jim Simons Sold Out
» More
Q2 2014

REGN Guru Trades in Q2 2014

Joel Greenblatt 881 sh (New)
Jim Simons 2,862 sh (New)
Ray Dalio 18,400 sh (New)
Mario Gabelli 2,295 sh (New)
Andreas Halvorsen 2,963,456 sh (+181.75%)
Vanguard Health Care Fund 2,795,500 sh (+60.34%)
Frank Sands 4,907,362 sh (+22.32%)
Ron Baron 7,109 sh (+16.85%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA
According to GuruFocus Insider Data, the largest insider sells during the past week were: Microsoft Corp, Regeneron Pharmaceuticals Inc., Activision Blizzard Inc. and Mid-America Apartment Communities. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 94.90
REGN's P/E(ttm) is ranked higher than
82% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 94.90 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 96.1
Current: 94.9

9.83
96.1
P/B 14.80
REGN's P/B is ranked lower than
57% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. REGN: 14.80 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 14.8

1.43
26.42
P/S 15.70
REGN's P/S is ranked higher than
55% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. REGN: 15.70 )
REGN' s 10-Year P/S Range
Min: 2.06   Max: 27.97
Current: 15.7

2.06
27.97
PFCF 72.10
REGN's PFCF is ranked higher than
86% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 72.10 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 72.1

9.29
2102
EV-to-EBIT 40.01
REGN's EV-to-EBIT is ranked higher than
89% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 40.01 )
REGN' s 10-Year EV-to-EBIT Range
Min: 4   Max: 2827.2
Current: 40.01

4
2827.2
Shiller P/E 339.00
REGN's Shiller P/E is ranked higher than
87% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 339.00 )
REGN' s 10-Year Shiller P/E Range
Min: 271.85   Max: 1446.63
Current: 339

271.85
1446.63
Current Ratio 5.46
REGN's Current Ratio is ranked higher than
78% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. REGN: 5.46 )
REGN' s 10-Year Current Ratio Range
Min: 2.17   Max: 20.69
Current: 5.46

2.17
20.69
Quick Ratio 5.14
REGN's Quick Ratio is ranked higher than
78% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. REGN: 5.14 )
REGN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 20.5
Current: 5.14

2.17
20.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 77.40
REGN's Price/Net Current Asset Value is ranked higher than
54% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. REGN: 77.40 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.18   Max: 2443.86
Current: 77.4

3.18
2443.86
Price/Tangible Book 14.90
REGN's Price/Tangible Book is ranked lower than
55% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. REGN: 14.90 )
REGN' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 22
Current: 14.9

0.86
22
Price/DCF (Projected) 18.80
REGN's Price/DCF (Projected) is ranked higher than
83% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 18.80 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 240.67
Current: 18.8

14.99
240.67
Price/Median PS Value 1.40
REGN's Price/Median PS Value is ranked higher than
59% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. REGN: 1.40 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.06
Current: 1.4

0.21
5.06
Price/Graham Number 7.70
REGN's Price/Graham Number is ranked higher than
82% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 7.70 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 7.27
Current: 7.7

1.24
7.27
Earnings Yield (Greenblatt) 2.50
REGN's Earnings Yield (Greenblatt) is ranked lower than
52% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. REGN: 2.50 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 2.5

1.3
24.9
Forward Rate of Return (Yacktman) -0.26
REGN's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. REGN: -0.26 )
REGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.8   Max: -0.3
Current: -0.26

-22.8
-0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The Company was incorporated in January 1988 in the State of New York. The Company currently has two marketed products: EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is the main cause of acquired blindness for people over the age of 65 in the United States and Europe; and ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available by prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The Company has 13 product candidates in clinical development, all of which were discovered in its research laboratories. Its Trap-based, late-stage programs are: EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as VEGF Trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment. The Company, together with its ex-U.S. collaborator Bayer HealthCare, is evaluating EYLEA in Phase 3 programs in patients with central retinal vein occlusion (CRVO), diabetic macular edema (DME), and choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The Company's manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. The Company's competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current an
» More Articles for REGN

Headlines

Articles On GuruFocus.com
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 
Weekly Top Insider Sells: REGN May 27 2013 
comment on REGN Mar 06 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 
52-Week High Companies: EC, MAT, ORLY, V, REGN Apr 16 2012 

More From Our Partners
Stock Market News for August 15, 2014 - Market News Aug 15 2014 - ZACKS

More From Other Websites
Regeneron Announces Upcoming 2014 Investor Conference Presentations Aug 19 2014
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Ring The NASDAQ Stock Market Opening Bell Aug 19 2014
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Ring The NASDAQ Stock Market Opening Bell Aug 19 2014
Regeneron Announces Upcoming 2014 Investor Conference Presentations Aug 19 2014
[video] Hot biotech drugs Aug 19 2014
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins Aug 18 2014
[video] Cramer: Market about Russia-Ukraine Aug 18 2014
Regeneron CEO: How I became a billionaire Aug 17 2014
[video] Eyeball injections equal eye-popping profits Aug 14 2014
[video] Red hot biotech stocks Aug 14 2014
Cramer: Is Street preparing for the worst? Aug 13 2014
Regeneron's Eye Drug Eylea Cleared in the EU for DME Aug 12 2014
REGENERON PHARMACEUTICALS INC Financials Aug 12 2014
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments Aug 11 2014
[video] Cramer's Mad Dash: Tesla breaking out Aug 11 2014
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema... Aug 11 2014
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema... Aug 11 2014
Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the... Aug 07 2014
Celgene: Five Reasons to Be Bullish Aug 06 2014
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress Aug 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide